GlassScriptPhysician profile
Troy W Bishop
NPI 1770543795
$3,426.29
in general payments reported to CMS, 2019-2025
31 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $732 · 2021: $1,194 · 2022: $651 · 2023: $29.14 · 2024: $110 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.04 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $446.90 | 2019-2022 | |
| Daiichi Sankyo INC. | $397.43 | 2019-2023 | Injectafer |
| Novo Nordisk INC | $396.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.42 | 2020-2024 | Airsupra |
| Abbvie INC. | $173.08 | 2021-2025 | |
| Lilly USA, LLC | $171.51 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $155.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $150.15 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $76.04 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $70.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.92 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $58.92 | 2019 | |
| Pfizer INC. | $50.87 | 2021-2022 | |
| Mylan Specialty L.P. | $49.79 | 2021-2024 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.21 | 2021-2025 | Repatha, Otezla |
| Abbott Laboratories | $45.07 | 2021-2025 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $41.35 | 2022 | |
| Endo Pharmaceuticals INC. | $39.48 | 2021 | |
| Eisai INC. | $39.32 | 2021 | |
| Shire North American Group INC | $34.83 | 2019 | |
| Exact Sciences Corporation | $34.47 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $26.41 | 2020-2021 | |
| Bausch Health US, LLC | $25.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.71 | 2021 | |
| Amarin Pharma, INC. | $25.47 | 2019 | |
| Esperion Therapeutics, INC. | $23.04 | 2020 | |
| Acella Pharmaceuticals, LLC | $17.25 | 2025 | NP Thyroid 60 |
| Medicure Pharma INC. | $14.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2025 | Xifaxan |
| Phadia US INC. | $14.00 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.